Panacea Biotec: 3,000 Shares Dematerialized in August 2026
Panacea Biotec reported that 3,000 shares were dematerialized in August 2026. Total dematerialized shares as of August 31, 2026, reached 6,11,08,526. This comprises 5,24,39,796 via NSDL and 86,68,730 via CDSL.
This is a standard disclosure of share dematerialization data, which is a routine process and does not involve any significant corporate action or financial event that would materially impact the company.
The announcement is a routine regulatory filing regarding share dematerialization and does not contain any information that would positively or negatively impact the company's outlook.
Panacea Biotec Limited has submitted details regarding the dematerialization of shares during August 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
As of August 31, 2026, the total number of shares dematerialized stood at 6,11,08,526. This includes 5,24,39,796 shares through NSDL and 86,68,730 shares through CDSL.
The company's Registrar and Transfer Agent, Skyline Financial Services Pvt. Ltd., has provided a certificate confirming these dematerialization figures as of August 31, 2026. The data shows a net increase of 3,000 shares dematerialized during August 2026, with NSDL showing a decrease and CDSL an increase, resulting in the final total.
The announcement was broadcast on September 7, 2026.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.